Outcomes of Neonatal Candidiasis: The Impact of Delayed Initiation of Antifungal Therapy

Table 2

Antibacterial use: comparison between mortality and survivor groups.

	Nonsurvivors; 𝑛=22	Survivors; 𝑛=41	𝑃 value
Days on antibacterial drugs before first positive fungal culture: mean	36.3	17.3	0.002
Total days on antibacterial drugs: mean	63.9	40	0.006
Antibacterial agents used before invasive fungal infection
Glycopeptides (vancomycin) (%)	20 (91)	28 (68)	0.06
Aminoglycosides (amikacin, gentamicin, tobramycin) (%)	18 (82)	29 (71)	0.34
3rd generation cephalosporins (cefotaxime, ceftazidime) (%)	21 (95)	26 (63)	0.003
Carbapenem (imipenem/cilastatin, meropenem) (%)	8 (36)	8 (19.5)	0.16
Anaerobic (clindamycin, metronidazole) (%)	6 (27)	6 (15)	0.32